Cell Expansion Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product (Consumables, Culture Flasks and Accessories, Instruments), By Cell Type (Mammalian, Human, Microbial, Others), By Application (Biopharmaceuticals, Tissue Culture & Engineering, Vaccine Production, Drug Development, Gene Therapy, Cancer Research, Stem Cell Research, Others), By End-use (Biopharmaceutical & Biotechnology Companies, Research Institutes, Cell Banks, Others), By Region and Competition, 2020-2030F

Market Overview

The Global Cell Expansion Market, valued at USD 16.78 Billion in 2024, is projected to experience a CAGR of 10.48% to reach USD 30.51 Billion by 2030. The global cell expansion market encompasses technologies and consumables utilized to facilitate the proliferation of cells in a controlled environment, which is a fundamental process in regenerative medicine, drug discovery, and biopharmaceutical production. Key drivers supporting this market's growth include the increasing prevalence of chronic diseases demanding advanced therapeutic solutions, rising investments in research and development activities for cell-based therapies, and growing demand for personalized medicine. According to the Alliance for Regenerative Medicine, in August 2023, there were 2,837 ongoing clinical trials in the regenerative medicine sector, an increase from 2,814 in 2022, underscoring the expanding application of cell expansion techniques. However, a significant challenge impeding market expansion is the high cost associated with advanced cell expansion technologies and the manufacturing processes for cell-based products.

Key Market Drivers

Advancements in regenerative medicine and cell and gene therapies represent a crucial impetus for the global cell expansion market. Progress in understanding and manipulating cellular processes has led to novel therapeutic modalities inherently reliant on efficient and scalable cell proliferation. Significant regulatory milestones underscore this trend. According to Forbes, in January 2024, the FDA approved Casgevy, a CRISPR gene-editing treatment, for transfusion-dependent beta thalassemia, following its approval for sickle cell disease in December 2023. Such approvals validate therapeutic potential and drive further investment into manufacturing components, making advanced cell expansion systems vital for commercial viability and patient access.

Increased research and development funding for cell-based therapies provides another powerful stimulus. Substantial investments from biopharmaceutical companies and venture capital fuel innovation in cell-based research, directly increasing the need for scalable cell expansion solutions. This commitment is evident in major strategic acquisitions. According to BioPharma Dive, in November 2024, Roche agreed to acquire Poseida Therapeutics for approximately $1 billion upfront, with potential for up to $1.5 billion including milestone payments, specifically to enhance its allogeneic cell therapy capabilities. These financial injections accelerate preclinical and clinical development, necessitating advanced cell expansion platforms. Consequently, the broader biopharmaceutical manufacturing sector is also growing. According to Pharmaceutical Technology, in October 2024, overall biologics capacity expanded to just above 6700 kL, highlighting the expanding industrial infrastructure supporting cell-based products and their underlying cell expansion requirements.

Download Free Sample Report

Key Market Challenges

The high cost associated with advanced cell expansion technologies and the manufacturing processes for cell-based products poses a significant barrier to the global cell expansion market's growth. These substantial financial outlays directly affect research and development budgets, creating hurdles for smaller organizations and new entrants to develop or scale their operations. The considerable capital expenditure required for specialized equipment and facilities, coupled with the ongoing operational expenses for maintaining sterile environments and expert personnel, results in elevated production costs for cell-based therapies.

This directly translates into a higher final price for these advanced therapeutic solutions, thereby restricting their accessibility and broader adoption within healthcare systems and for patients worldwide. According to the Institute for Clinical and Economic Review (ICER), in 2023, the average cost of a gene therapy was estimated between $1 million and $2 million per dose, while cell therapy treatments averaged $1 million. Such high costs limit the commercialization and widespread distribution of new cell expansion techniques and therapies, inhibiting overall market expansion.

Key Market Trends

Advancements in automated and digitalized cell expansion systems are fundamentally reshaping the cell expansion landscape by introducing unparalleled efficiency, consistency, and scalability. These systems minimize human intervention, reducing contamination risk and process variability inherent in manual operations. Digitalization enhances these benefits through real-time monitoring and data analytics, which are critical for maintaining stringent quality standards in large-scale cell production. According to the World Health Organization, global biopharmaceutical production capacity increased by 35% between 2020 and 2023, necessitating optimized manufacturing processes. Thermo Fisher Scientific exemplified this with the January 2024 launch of its Gibco CTS Cellmation Software, designed to integrate instruments across cell therapy manufacturing workflows, streamlining operations and reducing manual touchpoints. This strategic shift is pivotal for accelerating advanced therapy development and commercialization.

The increasing adoption of 3D cell culture technologies signifies a major paradigm shift, offering more physiologically relevant models than traditional 2D systems. These three-dimensional constructs, including spheroids and organoids, accurately mimic complex *in vivo* microenvironments and tissue architecture. This enhanced biological relevance leads to more predictive drug screening, improved disease modeling, and effective regenerative medicine development. Superior predictive capabilities contribute to reducing late-stage drug failures and accelerating therapeutic discovery. According to the U. S. National Institutes of Health, cell and gene therapy clinical trials increased by 45% in 2023, with over 3,200 active studies worldwide, many leveraging advanced 3D culture systems for preclinical validation. A June 2023 partnership between Stanford University and Sartorius, focused on developing scalable platforms for large-scale human induced pluripotent stem cell production, further underscores this industry commitment.

Segmental Insights

The Biopharmaceutical & Biotechnology Companies segment is rapidly expanding within the Global Cell Expansion Market due to several critical factors. These companies are at the forefront of developing advanced cell and gene therapies, regenerative medicines, and biologics, all of which require scalable and efficient cell expansion processes for research, clinical trials, and commercial production. The increasing prevalence of chronic diseases globally fuels the demand for innovative and personalized treatment options, driving significant investment in cell-based research and manufacturing within this sector. Furthermore, advancements in biotechnology, coupled with a supportive regulatory environment that facilitates the approval of novel cell-based treatments by bodies such as the U. S. Food and Drug Administration (FDA), are accelerating the development and commercialization efforts of biopharmaceutical and biotechnology firms.

Regional Insights

North America leads the global cell expansion market, driven by its sophisticated healthcare infrastructure and substantial investments in research and development from both public and private entities. These significant financial commitments accelerate the manufacturing of stem cells, regenerative medicines, and advanced cellular therapy products. The region also benefits from a strong presence of established biotechnology and biopharmaceutical companies, contributing to a vibrant ecosystem for innovation. Moreover, a highly supportive regulatory environment, exemplified by bodies like the U. S. Food and Drug Administration, streamlines the approval processes for novel cell-based therapies, fostering market growth and addressing the increasing demand for personalized medicine.

Recent Developments

• In April 2025, Thermo Fisher Scientific inaugurated its Advanced Therapies Collaboration Center (ATxCC) in Carlsbad, California. This 6,000-square-foot facility was established to accelerate the development and commercialization of cell therapies. It provides essential support to biopharmaceutical, biotech, and translational customers engaged in developing cell-based immunotherapies. The center enables cell therapy developers to leverage Thermo Fisher's product portfolio and process optimization expertise, facilitating comprehensive, end-to-end manufacturing workflows that can scale to achieve clinical and commercial success.

• In March 2025, Mesoblast commercially launched Ryoncil® (remestemcel-L-rknd), following its December 2024 approval by the Food and Drug Administration (FDA) as the first mesenchymal stromal cell (MSC) product in the United States. Ryoncil is indicated for treating steroid-refractory acute graft versus host disease in children, representing a significant new product in the cell expansion market. The product became commercially available within one quarter of receiving its regulatory approval, demonstrating a key advancement in bringing cell therapies to patients.

• In February 2025, PHC Holdings Corporation collaborated with CCRM to develop enhanced primary T-cell expansion culture processes. This joint initiative aimed to integrate PHC's LiCellGrow™ cell expansion system, currently under development, with CCRM's extensive knowledge in regenerative medicine and biomanufacturing. The goal was to establish new culture protocols that improve both the efficiency and quality of primary T-cell expansion for cell and gene therapies, thereby contributing to enhanced manufacturing outcomes and reduced production costs for cell-based therapeutics.

• In February 2024, Thermo Fisher Scientific and Multiply Labs expanded their partnership to automate cell expansion and separation processes within cell therapy manufacturing. This collaboration integrated Thermo Fisher's cell therapy instruments, including the Heracell VIOS Automated Access CO2 Incubator and the Gibco Cell Therapy Systems Rotea Counterflow Centrifugation System, with Multiply Labs' robotic technology. The initiative aimed to enhance the efficiency, reduce costs, and accelerate timelines in cell therapy development, ultimately supporting the scalability and accessibility of innovative cell therapies for a broader patient population.

Key Market Players

• Thermo Fisher Scientific, Inc.
• Corning Incorporated
• Merck KGaA
• Miltenyi Biotec B.V. & Co. KG
• Becton, Dickinson and Company (BD)
• Terumo BCT, Inc.
• Sartorius AG
• Takara Bio USA, Inc.
• TRINOVA BIOCHEM GmbH
• Upcyte Technologies GmbH

Report Scope:

In this report, the Global Cell Expansion Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Cell Expansion Market, By Product:

o   Consumables

o   Culture Flasks and Accessories

o   Instruments

• Cell Expansion Market, By Cell Type:

o   Mammalian

o   Human

o   Microbial

o   Others

• Cell Expansion Market, By Application:

o   Biopharmaceuticals

o   Tissue Culture & Engineering

o   Vaccine Production

o   Drug Development

o   Gene Therapy

o   Cancer Research

o   Stem Cell Research

o   Others

• Cell Expansion Market, By End-use:

o   Biopharmaceutical & Biotechnology Companies

o   Research Institutes

o   Cell Banks

o   Others

• Cell Expansion Market, By Region:

o   North America

§  United States

§  Canada

§  Mexico

o   Europe

§  France

§  United Kingdom

§  Italy

§  Germany

§  Spain

o   Asia Pacific

§  China

§  India

§  Japan

§  Australia

§  South Korea

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Cell Expansion Market.

Available Customizations:

Global Cell Expansion Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Global Cell Expansion Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]